Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80521 |
Name | lung non-squamous non-small cell carcinoma |
Definition | A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung non-squamous non-small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK rearrange | Ceritinib | lung non-squamous non-small cell carcinoma | sensitive | detail... |
MAP2K1 K57N | Trametinib | lung non-squamous non-small cell carcinoma | predicted - sensitive | detail... |
FGFR2 Y375C | Erdafitinib | lung non-squamous non-small cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01631279 | Phase Ib/II | TH-4000 | A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors | Terminated | USA | 1 |
NCT02657434 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUT | AUS | 19 |
NCT02810457 | Phase III | Carboplatin + FKB238 + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) | Completed | USA | ITA | ESP | DEU | 20 |
NCT03083691 | Phase II | Ipilimumab + Nivolumab | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | Unknown status | DEU | 0 |
NCT03267316 | Phase Ib/II | Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) | Unknown status | ESP | DEU | BEL | AUT | 7 |
NCT03293680 | Phase II | Pembrolizumab | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | Active, not recruiting | ESP | 0 |
NCT03409614 | Phase III | Cemiplimab + Ipilimumab Cemiplimab | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Active, not recruiting | USA | ITA | FRA | AUT | 14 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) | Recruiting | USA | ESP | DEU | CAN | BEL | 5 |
NCT03468426 | Phase I | BI 836880 + Ezabenlimab | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | Active, not recruiting | USA | GBR | FRA | ESP | DEU | AUS | 6 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03526887 | Phase II | Pembrolizumab | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) | Completed | ESP | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03786692 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | Recruiting | USA | 0 |
NCT03896074 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) | Unknown status | ITA | 0 |
NCT03906071 | Phase III | Docetaxel Nivolumab + Sitravatinib | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 4 |
NCT03909334 | Phase II | Osimertinib + Ramucirumab Osimertinib | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Recruiting | ITA | 0 |
NCT03976323 | Phase III | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Olaparib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 12 |
NCT03976375 | Phase III | Lenvatinib Lenvatinib + Pembrolizumab Docetaxel | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 10 |
NCT03994393 | Phase II | Durvalumab + Tremelimumab | Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE) | Active, not recruiting | AUS | 1 |
NCT04027946 | Phase II | LMB-100 + Pembrolizumab | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT04035486 | Phase III | Osimertinib Carboplatin + Osimertinib + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Osimertinib + Pemetrexed Disodium | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2) | Active, not recruiting | USA | GBR | FRA | CAN | AUS | 16 |
NCT04042558 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Pemetrexed Disodium Atezolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Cisplatin + Pemetrexed Disodium | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018) | Recruiting | FRA | 0 |
NCT04043195 | Phase Ib/II | Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) | Active, not recruiting | USA | 0 |
NCT04084717 | Phase II | Crizotinib | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | Recruiting | CAN | 0 |
NCT04093167 | Phase II | Pembrolizumab | Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC | Active, not recruiting | USA | CAN | 0 |
NCT04099836 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib | Terminated | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04154956 | Phase III | SAR408701 Docetaxel | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 17 |
NCT04163432 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium | Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (STAGGER) | Recruiting | USA | 0 |
NCT04173507 | Phase II | Avelumab + Talazoparib | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | Active, not recruiting | USA | 0 |
NCT04181060 | Phase III | Osimertinib Bevacizumab + Osimertinib | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Recruiting | USA | 0 |
NCT04194944 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Selpercatinib Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) | Active, not recruiting | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 18 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Active, not recruiting | USA | CAN | 1 |
NCT04245085 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Atezolizumab + Bevacizumab + Pemetrexed Disodium | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung) | Active, not recruiting | ESP | DEU | 3 |
NCT04262856 | Phase II | AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) | Active, not recruiting | USA | CAN | AUS | 4 |
NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
NCT04310007 | Phase II | Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | Suspended | USA | 0 |
NCT04332367 | Phase II | Carboplatin + Paclitaxel + Ramucirumab | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | Recruiting | USA | 0 |
NCT04351555 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib Carboplatin + Pemetrexed Disodium | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 18 |
NCT04394624 | Phase II | Ramucirumab + SAR408701 Pembrolizumab + Ramucirumab + SAR408701 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04) | Recruiting | USA | ESP | 4 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04447118 | Phase III | Pyrotinib Docetaxel | Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUS | 6 |
NCT04470674 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients | Withdrawn | USA | 0 |
NCT04524689 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701 | Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (CARMEN-LC05) | Recruiting | USA | FRA | ESP | 4 |
NCT04538664 | Phase III | Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 17 |
NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | Recruiting | CAN | 0 |
NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 7 |
NCT04619797 | Phase II | Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 14 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT04686305 | Phase I | MEDI5752 + Trastuzumab deruxtecan Trastuzumab deruxtecan Carboplatin + MEDI5752 + Trastuzumab deruxtecan Durvalumab + Pemetrexed Disodium + Trastuzumab deruxtecan Carboplatin + Durvalumab + Trastuzumab deruxtecan Cisplatin + Durvalumab + Trastuzumab deruxtecan | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 10 |
NCT04691817 | Phase Ib/II | Atezolizumab + Tocilizumab | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | Recruiting | USA | 0 |
NCT04758949 | Phase II | Nivolumab FL-101 + Nivolumab FL-101 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT04765059 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL) | Recruiting | USA | ITA | ESP | DEU | AUT | 2 |
NCT04772235 | Phase I | Osimertinib + Repotrectinib | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM) | Recruiting | ESP | 0 |
NCT04786964 | Phase III | Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Cosibelimab + Pemetrexed Disodium Carboplatin + Cosibelimab + Pemetrexed Disodium | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO) | Terminated | 8 | |
NCT04822298 | Phase I | AMG 160 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | AUT | AUS | 0 |
NCT04865250 | Phase II | Atezolizumab + Carboplatin + Nab-paclitaxel | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP) | Recruiting | DEU | 0 |
NCT04914897 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 7 |
NCT04925986 | Phase II | Pembrolizumab + Sitravatinib | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | Active, not recruiting | USA | 0 |
NCT04928846 | Phase III | Telisotuzumab vedotin Docetaxel | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 19 |
NCT04956692 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | Active, not recruiting | USA | FRA | ESP | 13 |
NCT04958811 | Phase II | Atezolizumab + Bevacizumab + Tiragolumab | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | Recruiting | USA | 0 |
NCT04971187 | Phase II | Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Pemetrexed Disodium | Bintrafusp Alfa With Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Locally Advanced or Metastatic Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04988295 | Phase III | Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 21 |
NCT04993677 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 | A Study of SEA-CD40 Given With Other Drugs in Cancers | Active, not recruiting | USA | FRA | ESP | DEU | CAN | 1 |
NCT04995523 | Phase Ib/II | AZD2936 | Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01) | Recruiting | USA | GBR | FRA | ESP | BEL | AUS | 10 |
NCT05017025 | Phase Ib/II | LY3295668 + Osimertinib | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05118854 | Phase II | Cisplatin + Pemetrexed Disodium + Sotorasib Carboplatin + Pemetrexed Disodium + Sotorasib | A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | Recruiting | USA | 0 |
NCT05120349 | Phase III | Osimertinib | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2) | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 14 |
NCT05170204 | Phase III | Durvalumab Alectinib Pralsetinib Entrectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | GBR | CAN | AUS | 13 |
NCT05184712 | Phase III | Carboplatin + Pemetrexed Disodium AK112 + Pemetrexed Disodium Pemetrexed Disodium AK112 + Carboplatin + Pemetrexed Disodium | Phase 3 Clinical Study of AK112 for NSCLC Patients | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 1 |
NCT05245071 | Phase II | SAR408701 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06) | Recruiting | USA | ITA | FRA | ESP | BEL | 2 |
NCT05338970 | Phase III | Patritumab deruxtecan | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 11 |
NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05400577 | Phase II | Sotorasib | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | Withdrawn | USA | 0 |
NCT05401110 | Phase I | Carotuximab + Osimertinib | Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05403385 | Phase II | Carboplatin + EOS100850 + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | Recruiting | USA | ITA | FRA | ESP | BEL | 3 |
NCT05403554 | Phase I | NI-1801 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | Recruiting | ITA | FRA | 0 |
NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Active, not recruiting | USA | FRA | ESP | BEL | 0 |
NCT05469178 | Phase Ib/II | Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05492682 | Phase I | Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Recruiting | DEU | 0 |
NCT05513703 | Phase II | Telisotuzumab vedotin | A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | ITA | FRA | DEU | AUS | 4 |
NCT05557591 | Phase II | Cemiplimab BNT116 + Cemiplimab | Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 >= 50% | Recruiting | USA | 0 |
NCT05567055 | Phase II | Capmatinib | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | Not yet recruiting | USA | 0 |
NCT05601973 | Phase II | Amivantamab-vmjw + Bevacizumab + Lazertinib | AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung) | Recruiting | ITA | GBR | FRA | ESP | 3 |
NCT05607550 | Phase III | Furmonertinib | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | AUS | 2 |
NCT05652868 | Phase I | MYTX-011 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05692999 | Phase III | Pembrolizumab + Pemetrexed Disodium | Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse) | Recruiting | FRA | 0 |
NCT05704634 | Phase I | Cemiplimab + Sarilumab | A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. | Recruiting | USA | 0 |
NCT05746481 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab | Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | Recruiting | USA | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Recruiting | USA | 0 |
NCT05800015 | Phase II | Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05801029 | Phase II | Amivantamab-vmjw + Osimertinib | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA) | Recruiting | CAN | 6 |
NCT05882734 | Phase Ib/II | Cemiplimab + M1774 | M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | Not yet recruiting | USA | 0 |
NCT05973773 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Zipalertinib Carboplatin + Pemetrexed Disodium + Zipalertinib Pemetrexed Disodium Cisplatin + Pemetrexed Disodium + Zipalertinib | A Study of Zipalertinib and Chemotherapy Compared With Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion. (REZILIENT3) | Recruiting | USA | 0 |